close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lunai Bioworks Inc. - Common Stock (NQ:RENB)

1.420 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lunai Bioworks Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A LEADING LAW FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
WHY: NEW YORK, NY - (NewMediaWire) - February 20, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Renovaro... 
Via TheNewswire.com
News headline image
RENB SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation – RENB
From The Rosen Law Firm PA
Via GlobeNewswire
Cutting Edge Blood Genetic Testing Using Nvidia AI Chips Emerging from Acquisition of Dutch Based Cyclomics; Aim to Disrupt Cancer Diagnosis and Treatment: Renovaro Biosciences Inc. (Nasdaq: RENB)
Via Get News
Topics Artificial Intelligence
News headline image
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
From Renovaro Biosciences Inc.
Via GlobeNewswire
News headline image
Statement of Renovaro Inc
From Renovaro Biosciences Inc.
Via GlobeNewswire
BioMedNewsBreaks – Renovaro Inc. (NASDAQ: RENB) Fusing AI and Biotech to Accelerate Personalized Medicine, GEDiCube, Cyclomics Enter LOI to ‘Change the Field’
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
ROSEN, A LEADING NATIONAL FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation – RENB
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
From Renovaro Biosciences Inc.
Via GlobeNewswire
News headline image
AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
From Renovaro Biosciences Inc.
Via GlobeNewswire
Patients with Swelling Disorder See New Gene Therapy as Godsend
Via Investor Brand Network
Study Explains Why Immunotherapy Could Trigger Colitis in Cancer Patients
Via Investor Brand Network
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Results of Special Meeting
Via Investor Brand Network
News headline image
Renovaro Biosciences Announces Results of Special Meeting of Shareholders
From Renovaro Biosciences Inc.
Via GlobeNewswire
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD
Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024 
From Renovaro Biosciences Inc.
Via GlobeNewswire
Fruit Fly Study Opens Door to Novel Immunotherapy Approach Against Cancer
Via Investor Brand Network
News headline image
RENOVARO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Renovaro Biosciences Inc. - RENB
From Kahn Swick & Foti, LLC
Via Business Wire
Study Shows Ongoing Benefits Once Immunotherapy Stops
Via Investor Brand Network
Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes
Via Investor Brand Network
Researchers Harnessing Immune System to Fight Cancer More Effectively
Via Investor Brand Network
Study Says Patients on Gene Therapy Need Long-Term Monitoring
Via Investor Brand Network
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Poised to Spearhead Advancements in Battle Against Diseases, Harness Cutting-Edge AI Technology
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Opportunity in Largely Untapped Precision Medicine Market
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Unlocking AI investment opportunities in healthcare
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities. 
Via MarketBeat
Topics Artificial Intelligence ETFs
How Immunotherapy Is Cementing a Role in Cancer Treatment
Via Investor Brand Network
Renovaro Biosciences Inc. (NASDAQ: RENB) CEO Provides Update on Combination with AI Expert GEDiCube Intl Ltd. in Letter to Shareholders
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI and Biotherapeutics
Via Investor Brand Network
Topics Artificial Intelligence
Renovaro Biosciences Inc. (NASDAQ: RENB) Announces Three New Members to Board of Directors as Definitive Agreement with GEDiCube Announced
Via Investor Brand Network
Topics Artificial Intelligence Derivatives
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today